Regen Biopharma Inc (RGBP) 0.1200 $RGBP
Regen BioPharma doses mice under its safety and tolerability study of HemaXellerate for aplastic anemia
M2 - Fri Jul 10, 3:36AM CDT
Biotechnology company Regen BioPharma (OTCBB:RGBP) (OTC PINK:RGBP) announced on Thursday the successful dosing of mice lacking an immune system under its safety and tolerability study with its proprietary aplastic anemia cell therapy drug candidate, HemaXellerate.
New Studies & Research Evaluating Stem Cell Therapy Treatments for Bone Marrow Diseases & Conditions Look to Identify Next-Generation Therapies For New Pre-Clinical and Phase I/II Clinical Trials
PR Newswire - Thu Jul 09, 7:30AM CDT
Researchers & Biotech companies are constantly searching for tailor-made treatment plans for bone marrow conditions such as aplastic anemia as part of an emerging precision medicine movement which likely will help doctors optimize treatment for this rare and deadly blood condition. Even with the Biotechnology struggling a bit this week in markets, companies in focus today with news and current developments are Regen BioPharma, Inc. (OTCBB: RGBP), Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), Horizon Pharma plc (NASDAQ: HZNP), AstraZeneca Pharmaceuticals Co. (NYSE: AZN) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
RPTP: 14.51 (-0.34), IRWD: 11.44 (-0.06), AZN: 66.45 (+1.90), HZNP: 35.94 (+1.13), OCLS: 1.60 (+0.02)
Regen BioPharma, Inc. Reports Successful Dosing of HemaXellerate in FDA-Requested GLP Animal Study
PR Newswire - Thu Jul 09, 6:45AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) (OTC: RGBP) reported today the successful dosing of mice lacking an immune system in a safety and tolerability study with HemaXellerate, the Company's proprietary aplastic anemia cell therapy drug candidate. The experiment is being conducted under Good Laboratory Practices (cGLP) by Charles River Laboratories. Charles River Laboratories, established in 1947, is a well respected NYSE-traded contract research organization with 8,500 employees specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries.
Regen BioPharma, Inc. Announces Presentation at the International Society for Stem Cell Research 13th Annual Meeting in Stockholm, Sweden
PR Newswire - Tue Jun 16, 7:30AM CDT
Regen BioPharma Inc (OTCBB: RGBP) (OTC PINK: RGBP) announced today that its abstract was accepted for presentation at the International Society for Stem Cell Research Annual Meeting, June 24-27, in Stockholm, Sweden. Dr. Christine Ichim, the Company's Director of Molecular Therapeutics, will be presenting preclinical data delineating the effects of the Company's gene silencing drugs on stem cells.
Regen BioPharma, Inc. Receives Notice of Allowance for U.S. Patent for Screening of Small Molecules Against Its Nuclear Receptor Target
Marketwired - Fri Jun 12, 9:16AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that it received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application # 13/652,395. This patent, with a priority date of 2008, covers screening mechanisms for identification of small molecules that can modulate the function of a nuclear receptor target that was shown by Dr. Christine Ichim, Regen's Director of Molecular Therapeutics and University of Toronto Hematologist Dr. Richard Wells to be involved in maintenance of the cancer stem cells.
Advanced Immunotherapy Clinical Trials for Cancer Therapies & Breast Cancer Treatments Focus on Developing Innovative Therapeutics & Gene-Silencing Cell Studies
PR Newswire - Wed Jun 10, 7:35AM CDT
Clinical Trials and Innovation Therapies continue to have the potential to drive the pharma and biotech sectors for the final six months of 2015 as forecasts point to the potential for another prosperous year. Cancer new treatments show promise of immuno-oncology therapies as further studies & trials continue to progress. Biotech Companies in focus today are Regen BioPharma, Inc. (OTC: RGBP), Sanofi SA (NYSE: SNY), Vical Incorporated (NASDAQ: VICL), RXi Pharmaceuticals Corporation (NASDAQ: RXII), Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI) & Neuralstem, Inc. (NYSE: CUR)
VICL: 0.70 (unch), RXII: 0.53 (+0.05), RCPI: 1.40 (+0.11), SNY: 51.49 (+2.71), CUR: 1.69 (-0.01)
Cancer Clinical Trials Expert Dr. Santosh Kesari to Assist Regen BioPharma, Inc. in Addressing FDA Questions Regarding Planned dCellVax Immunotherapy Clinical Trial for Breast Cancer
PR Newswire - Wed Jun 10, 6:55AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) (OTC: RGBP) announced today the initiation of a collaboration with Dr. Santosh Kesari , Professor and Director of Neuro-oncology at University of California San Diego . The goals of the collaboration is to address questions posed by the FDA regarding Regn BioPharma, Inc.'s planned Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer and to modify the existing Investigational New Drug application in order to maximize the probability of clinical trial success . The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 months.
Regen BioPharma, Inc. Recruits Retinoid Experts Dr. Hinrich Gronemeyer, Dr. William S. Blaner, and Dr. Louise Purton to Serve on Scientific Advisory Board
Marketwired - Thu Jun 04, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the appointment of Dr. Hinrich Gronemeyer, Dr. William S. Blaner, and Dr. Louise Purton to its Scientific Advisory Board. These three experts in the field of retinoid biology have been recruited by Regen BioPharma, Inc. in order to provide the Company with the expertise necessary to accelerate Regen's differentiation therapy small molecule drug discovery platform. This platform aims to design small molecules that can induce differentiation of cancer stem cells by designing ligands to nuclear receptors involved in maintaining stem cell properties of cancer stem cells.
Regen BioPharma Files Patent Application on mRNA Dendritic Cell Cancer Immunotherapeutic
Marketwired - Wed May 27, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the filing of a United States patent application covering mRNA delivered tumor antigens to dendritic cells as a means of inducing tumor immunity. The current work builds upon the Company's Cancer Immunotherapy Platform. This patent application covers intellectual property that provides a means of specifically inducing dendritic cells to internally generate tumor antigens, a process which is believed to be more effective then exogenously administering antigens to dendritic cells. The majority of dendritic cell therapeutics involve "feeding" dendritic cells antigens, this leads to a different type of immune response than if the antigens are generated inside of the dendritic cell.
Regen BioPharma, Inc. Makes Three Presentations at the 13th International Symposium on Myelodysplastic Syndromes Held April 29 to May 2, 2015 in Washington, DC
Marketwired - Tue May 05, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the Company has made presentations at 13th International Symposium on Myelodysplastic Syndromes held April 29 to May 2, 2015 in Washington, D.C.
Regen BioPharma Sees Opportunities Resulting from AACR Conference Attendance and Presentation
Marketwired - Mon Apr 27, 7:30AM CDT
Spokespersons for Regen BioPharma, Inc. (OTCBB: RGBP) (OTC PINK: RGBP) commented today regarding significant milestones presented by the Company at the 2015 American Association for Cancer Research Annual Meeting (AACR) as well as potential partnering opportunities that resulted from its presence at the event
Regen BioPharma, Inc. Engages Charles River Laboratories to Initiate FDA-Requested Study to Support Initiation of HemaXellerate Clinical Trial
Marketwired - Wed Apr 22, 7:31AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that it has engaged Charles River Laboratories to initiate a Good Laboratory Practices (GLP) mouse toxicity study with regards to HemaXellerate. HemaXellerate, a therapy under development by Regen, is a cellular drug designed to heal damaged bone marrow.
Regen BioPharma Recruits Renowned Cancer Stem Cell Experts to Scientific Advisory Board
Marketwired - Thu Apr 16, 3:01PM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the recruitment of 3 internationally-renowned cancer stem cell experts to its scientific advisory board. The addition is a result of the company's increasing advances in the development of therapeutics targeting what is believed to be "the root of cancer" which is the cancer stem cell. The following is a description of the new members:
Regen BioPharma Narrows Selection of CRO Candidates for HemaXellerate GLP Safety Studies Requested by the FDA
Marketwired - Mon Apr 13, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP), (OTC PINK: RGBP) announced today that it has narrowed the Contract Research Organization (CRO) selection process to two candidates. The selected candidate will conduct the HemaXellerate Good Laboratory Practice (GLP) safety study requested by the US Food and Drug Administration ( FDA). This study will consist of an additional set of animal safety studies on HemaXellerate in preparation for submission to the FDA for permission to initiate "First in Human" use of HemaXellerate. HemaXellerate is a proposed therapeutic product for treating aplastic anemia.
Regen BioPharma Inc. Announces Small Molecule Drug Discovery Milestones at the American Association for Cancer Research's 2015 Annual Meeting
Marketwired - Thu Apr 09, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the acceptance of its abstract "Discovery of retinoic acids as low affinity inhibitors of the leukemia stem cell target NR2F6" at the American Association for Cancer Research Annual Meeting taking place April 18-22, 2015 in Philadelphia, Pennsylvania.
Regen BioPharma Inc. to Present Multiple Presentations at the 13th International Symposium on Myelodysplastic Syndromes
Marketwired - Tue Apr 07, 9:22AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the 13th International Symposium on Myelodysplastic Syndromes has accepted three presentations prepared by Regen BioPharma Inc. The accepted abstracts highlight the work being done in the Company's area of expertise in Aplastic Anemia and Myelodysplastic Syndrome. The link to the conference is http://mds.kenes.com
Regen BioPharma Expands Its Differentiation Therapy of Cancer Stem Cells Platform With Filing of Patent Applications on Silencing of NR2F2
Marketwired - Mon Apr 06, 11:00AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the expansion of its cancer stem cell intellectual property portfolio to include targeting of the gene NR2F2 (also known as COUP-TFII), a closely related family member to the cancer stem cell gene NR2F6, with the filing of two patent applications. Patent application #14588374 is for Treatment of Myelodysplastic Syndrome by Inhibition of NR2F2 and patent application # 14588373 is for Methods and Compositions for treatment of cancer by inhibition of NR2F2.
Regen BioPharma CEO Discusses Recent Financings, New Laboratory Facilities and Preferred Stock Dividend
Marketwired - Wed Apr 01, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) Chairman & CEO David Koos provided the following update and clarification on recent financings done by the Company, along with new laboratory facilities and preferred stock dividend announcements:
Regen BioPharma Announces Presentation of DiffronC at Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics
Marketwired - Tue Mar 31, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today that its abstract entitled "Development of DiffronC gene silencing technology for silencing of the novel leukemia stem cell target NR2F6" was accepted for presentation at the Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics, April 8 - 11, 2015.
Regen BioPharma doses mice under its safety and tolerability study of HemaXellerate for aplastic anemia
M2 - Fri Jul 10, 3:36AM CDT
Biotechnology company Regen BioPharma (OTCBB:RGBP) (OTC PINK:RGBP) announced on Thursday the successful dosing of mice lacking an immune system under its safety and tolerability study with its proprietary aplastic anemia cell therapy drug candidate, HemaXellerate.
New Studies & Research Evaluating Stem Cell Therapy Treatments for Bone Marrow Diseases & Conditions Look to Identify Next-Generation Therapies For New Pre-Clinical and Phase I/II Clinical Trials
PR Newswire - Thu Jul 09, 7:30AM CDT
Researchers & Biotech companies are constantly searching for tailor-made treatment plans for bone marrow conditions such as aplastic anemia as part of an emerging precision medicine movement which likely will help doctors optimize treatment for this rare and deadly blood condition. Even with the Biotechnology struggling a bit this week in markets, companies in focus today with news and current developments are Regen BioPharma, Inc. (OTCBB: RGBP), Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), Horizon Pharma plc (NASDAQ: HZNP), AstraZeneca Pharmaceuticals Co. (NYSE: AZN) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
RPTP: 14.51 (-0.34), IRWD: 11.44 (-0.06), AZN: 66.45 (+1.90), HZNP: 35.94 (+1.13), OCLS: 1.60 (+0.02)
Regen BioPharma, Inc. Reports Successful Dosing of HemaXellerate in FDA-Requested GLP Animal Study
PR Newswire - Thu Jul 09, 6:45AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) (OTC: RGBP) reported today the successful dosing of mice lacking an immune system in a safety and tolerability study with HemaXellerate, the Company's proprietary aplastic anemia cell therapy drug candidate. The experiment is being conducted under Good Laboratory Practices (cGLP) by Charles River Laboratories. Charles River Laboratories, established in 1947, is a well respected NYSE-traded contract research organization with 8,500 employees specializing in a variety of pre-clinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries.
Regen BioPharma, Inc. Announces Presentation at the International Society for Stem Cell Research 13th Annual Meeting in Stockholm, Sweden
PR Newswire - Tue Jun 16, 7:30AM CDT
Regen BioPharma Inc (OTCBB: RGBP) (OTC PINK: RGBP) announced today that its abstract was accepted for presentation at the International Society for Stem Cell Research Annual Meeting, June 24-27, in Stockholm, Sweden. Dr. Christine Ichim, the Company's Director of Molecular Therapeutics, will be presenting preclinical data delineating the effects of the Company's gene silencing drugs on stem cells.
Regen BioPharma, Inc. Receives Notice of Allowance for U.S. Patent for Screening of Small Molecules Against Its Nuclear Receptor Target
Marketwired - Fri Jun 12, 9:16AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that it received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application # 13/652,395. This patent, with a priority date of 2008, covers screening mechanisms for identification of small molecules that can modulate the function of a nuclear receptor target that was shown by Dr. Christine Ichim, Regen's Director of Molecular Therapeutics and University of Toronto Hematologist Dr. Richard Wells to be involved in maintenance of the cancer stem cells.
Advanced Immunotherapy Clinical Trials for Cancer Therapies & Breast Cancer Treatments Focus on Developing Innovative Therapeutics & Gene-Silencing Cell Studies
PR Newswire - Wed Jun 10, 7:35AM CDT
Clinical Trials and Innovation Therapies continue to have the potential to drive the pharma and biotech sectors for the final six months of 2015 as forecasts point to the potential for another prosperous year. Cancer new treatments show promise of immuno-oncology therapies as further studies & trials continue to progress. Biotech Companies in focus today are Regen BioPharma, Inc. (OTC: RGBP), Sanofi SA (NYSE: SNY), Vical Incorporated (NASDAQ: VICL), RXi Pharmaceuticals Corporation (NASDAQ: RXII), Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI) & Neuralstem, Inc. (NYSE: CUR)
VICL: 0.70 (unch), RXII: 0.53 (+0.05), RCPI: 1.40 (+0.11), SNY: 51.49 (+2.71), CUR: 1.69 (-0.01)
Cancer Clinical Trials Expert Dr. Santosh Kesari to Assist Regen BioPharma, Inc. in Addressing FDA Questions Regarding Planned dCellVax Immunotherapy Clinical Trial for Breast Cancer
PR Newswire - Wed Jun 10, 6:55AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) (OTC: RGBP) announced today the initiation of a collaboration with Dr. Santosh Kesari , Professor and Director of Neuro-oncology at University of California San Diego . The goals of the collaboration is to address questions posed by the FDA regarding Regn BioPharma, Inc.'s planned Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer and to modify the existing Investigational New Drug application in order to maximize the probability of clinical trial success . The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 months.
Regen BioPharma, Inc. Recruits Retinoid Experts Dr. Hinrich Gronemeyer, Dr. William S. Blaner, and Dr. Louise Purton to Serve on Scientific Advisory Board
Marketwired - Thu Jun 04, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the appointment of Dr. Hinrich Gronemeyer, Dr. William S. Blaner, and Dr. Louise Purton to its Scientific Advisory Board. These three experts in the field of retinoid biology have been recruited by Regen BioPharma, Inc. in order to provide the Company with the expertise necessary to accelerate Regen's differentiation therapy small molecule drug discovery platform. This platform aims to design small molecules that can induce differentiation of cancer stem cells by designing ligands to nuclear receptors involved in maintaining stem cell properties of cancer stem cells.
Regen BioPharma Files Patent Application on mRNA Dendritic Cell Cancer Immunotherapeutic
Marketwired - Wed May 27, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the filing of a United States patent application covering mRNA delivered tumor antigens to dendritic cells as a means of inducing tumor immunity. The current work builds upon the Company's Cancer Immunotherapy Platform. This patent application covers intellectual property that provides a means of specifically inducing dendritic cells to internally generate tumor antigens, a process which is believed to be more effective then exogenously administering antigens to dendritic cells. The majority of dendritic cell therapeutics involve "feeding" dendritic cells antigens, this leads to a different type of immune response than if the antigens are generated inside of the dendritic cell.
Regen BioPharma, Inc. Makes Three Presentations at the 13th International Symposium on Myelodysplastic Syndromes Held April 29 to May 2, 2015 in Washington, DC
Marketwired - Tue May 05, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the Company has made presentations at 13th International Symposium on Myelodysplastic Syndromes held April 29 to May 2, 2015 in Washington, D.C.
Regen BioPharma Sees Opportunities Resulting from AACR Conference Attendance and Presentation
Marketwired - Mon Apr 27, 7:30AM CDT
Spokespersons for Regen BioPharma, Inc. (OTCBB: RGBP) (OTC PINK: RGBP) commented today regarding significant milestones presented by the Company at the 2015 American Association for Cancer Research Annual Meeting (AACR) as well as potential partnering opportunities that resulted from its presence at the event
Regen BioPharma, Inc. Engages Charles River Laboratories to Initiate FDA-Requested Study to Support Initiation of HemaXellerate Clinical Trial
Marketwired - Wed Apr 22, 7:31AM CDT
Regen BioPharma, Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that it has engaged Charles River Laboratories to initiate a Good Laboratory Practices (GLP) mouse toxicity study with regards to HemaXellerate. HemaXellerate, a therapy under development by Regen, is a cellular drug designed to heal damaged bone marrow.
Regen BioPharma Recruits Renowned Cancer Stem Cell Experts to Scientific Advisory Board
Marketwired - Thu Apr 16, 3:01PM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the recruitment of 3 internationally-renowned cancer stem cell experts to its scientific advisory board. The addition is a result of the company's increasing advances in the development of therapeutics targeting what is believed to be "the root of cancer" which is the cancer stem cell. The following is a description of the new members:
Regen BioPharma Narrows Selection of CRO Candidates for HemaXellerate GLP Safety Studies Requested by the FDA
Marketwired - Mon Apr 13, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP), (OTC PINK: RGBP) announced today that it has narrowed the Contract Research Organization (CRO) selection process to two candidates. The selected candidate will conduct the HemaXellerate Good Laboratory Practice (GLP) safety study requested by the US Food and Drug Administration ( FDA). This study will consist of an additional set of animal safety studies on HemaXellerate in preparation for submission to the FDA for permission to initiate "First in Human" use of HemaXellerate. HemaXellerate is a proposed therapeutic product for treating aplastic anemia.
Regen BioPharma Inc. Announces Small Molecule Drug Discovery Milestones at the American Association for Cancer Research's 2015 Annual Meeting
Marketwired - Thu Apr 09, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the acceptance of its abstract "Discovery of retinoic acids as low affinity inhibitors of the leukemia stem cell target NR2F6" at the American Association for Cancer Research Annual Meeting taking place April 18-22, 2015 in Philadelphia, Pennsylvania.
Regen BioPharma Inc. to Present Multiple Presentations at the 13th International Symposium on Myelodysplastic Syndromes
Marketwired - Tue Apr 07, 9:22AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today that the 13th International Symposium on Myelodysplastic Syndromes has accepted three presentations prepared by Regen BioPharma Inc. The accepted abstracts highlight the work being done in the Company's area of expertise in Aplastic Anemia and Myelodysplastic Syndrome. The link to the conference is http://mds.kenes.com
Regen BioPharma Expands Its Differentiation Therapy of Cancer Stem Cells Platform With Filing of Patent Applications on Silencing of NR2F2
Marketwired - Mon Apr 06, 11:00AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the expansion of its cancer stem cell intellectual property portfolio to include targeting of the gene NR2F2 (also known as COUP-TFII), a closely related family member to the cancer stem cell gene NR2F6, with the filing of two patent applications. Patent application #14588374 is for Treatment of Myelodysplastic Syndrome by Inhibition of NR2F2 and patent application # 14588373 is for Methods and Compositions for treatment of cancer by inhibition of NR2F2.
Regen BioPharma CEO Discusses Recent Financings, New Laboratory Facilities and Preferred Stock Dividend
Marketwired - Wed Apr 01, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) Chairman & CEO David Koos provided the following update and clarification on recent financings done by the Company, along with new laboratory facilities and preferred stock dividend announcements:
Regen BioPharma Announces Presentation of DiffronC at Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics
Marketwired - Tue Mar 31, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today that its abstract entitled "Development of DiffronC gene silencing technology for silencing of the novel leukemia stem cell target NR2F6" was accepted for presentation at the Cold Spring Harbor Conference on RNA & Oligonucleotide Therapeutics, April 8 - 11, 2015.
